Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children

By Raz R.   Dagan R.   Gallil A.   Brill G.   Kassis I.   Koren R.  

Vaccine, Vol. 14, Iss. 3, 1996-02 ,pp. : 207-211

Elsevier

Access to resources Recommend Favorite

Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine

By Netter H.J.   Woo W.-P.   Tindle R.   Macfarlan R.I.   Gowans E.J.  

Vaccine, Vol. 21, Iss. 21, 2003-06 ,pp. : 2692-2697

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4 and 6 months of age

By The Kaiser-UCLA Vaccine Study Group   Greenberg D.P.   Vadheim C.M.   Marcy S.M.   Partridge S.   Jing J.   Chung-Yin C.   Greene T.   Margolis H.S.   Ward J.I.  

Vaccine, Vol. 14, Iss. 8, 1996-06 ,pp. : 811-816

Elsevier

Access to resources Recommend Favorite

Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children

By Egemen A.   Aksit S.   Kurugol Z.   Erensoy S.   Bilgic A.   Akilli M.  

Vaccine, Vol. 16, Iss. 16, 1998-10 ,pp. : 1511-1515

Elsevier

Access to resources Recommend Favorite

Subtype specificity of anti-HBs antibodies produced by human B-cell lines isolated from normal individuals vaccinated with recombinant hepatitis B vaccine

By Shokrgozar M.A.   Shokri F.  

Vaccine, Vol. 20, Iss. 17, 2002-05 ,pp. : 2215-2220

Elsevier

Access to resources Recommend Favorite